With Adoption in Developing Economies, the Anti-Microbial/Antifungal Tests Market Will Reach New Heights

Microbial and fungal infections are major causes of death worldwide and can even lead to epidemics, putting a significant economic burden on countries, particularly developing ones. Prevention is a far better solution than cure for preventing the spread of such infections, which can be accomplished by isolating infected cases and performing primary screening tests. FMI has conducted a decade-long analysis of the global anti-microbial/anti-fungal tests market in its report titled ‘Anti-microbial/Anti-fungal Tests Market: Global Industry Analysis 2012-2016 and Opportunity Assessment 2017-2027.’ From 2017 to 2027, the anti-microbial/anti-fungal tests market is expected to grow at a 6% CAGR.

Request to View Sample Copy of [email protected] https://www.futuremarketinsights.com/reports/sample/rep-gb-5566

Region – Robust Healthcare Infrastructure in North America Enables Rapid Anti-Microbial/ Anti-Fungal Testing 

North America has the highest regional contribution and is expected to account for roughly one-third of the anti-microbial/antifungal tests market by the end of the forecast period. The market for anti-microbial/anti-fungal tests in North America is expected to exceed a billion dollars by 2027, making it the only region to do so. Most physicians on the continent order diagnostic tests before beginning treatment, fueling demand for anti-microbial/anti-fungal test kits. Furthermore, there is widespread awareness of the adverse effects of certain drugs, and patients frequently prefer to be fully diagnosed before seeking treatment.

Test Type – Molecular Based Tests Critical in Anti-Microbial/ Anti-Fungal Tests Market 

Molecular-based tests dominated the global anti-microbial/anti-fungal tests market by test type in 2017 and are expected to maintain this dominance for the foreseeable future. Molecular-based tests have a market attractiveness index of 2.6, which is significantly higher than the market attractiveness index of all other test types in the anti-microbial/anti-fungal tests market. Companies should concentrate their efforts within the molecular-based tests segment on the PCR Test sub-segment, which is roughly three times the size of the DNA microarray tests in terms of value. For the decadal study, the PCR test segment is expected to grow at a CAGR of 6.4%.

Infection Type – Target Antimicrobial Resistance and Microbial Infection Segments in Anti-Microbial/ Anti-Fungal Tests Market 

The antimicrobial and microbial resistance segments are the ones to watch because they account for nearly 3/4th of the global anti-microbial/anti-fungal tests market. The multi-drug-resistant mycobacterium tuberculosis sub-segment is the most populous in the antimicrobial resistance segment and is expected to grow rapidly. Along with multi-drug-resistant mycobacterium tuberculosis, the microbial infection segment has significant potential in the anti-microbial/anti-fungal tests market, with a value approaching US$ 1 billion by the end of 2027.

End User – Hospitals and Reference Labs Demand Antimicrobial/ Antifungal Testing Kits 

Hospitals and reference labs are by far the most important end users in the anti-microbial/anti-fungal tests market. Because of increased awareness of various treatment options and diagnostic tools for detecting and curing various diseases, global per-capita healthcare spending has more than doubled. In the market for anti-microbial/anti-fungal tests, reference labs are expected to grow faster than hospitals.

Request to View [email protected] https://www.futuremarketinsights.com/toc/rep-gb-5566

Competition Dashboard in the Anti-Microbial/ Anti-Fungal Tests Market 

The companies profiled in the report are Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories, Bruker Corporation, Danaher Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience, Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen N.V., Quidel Corporation, and Thermo Fisher Scientific Inc.


In Asia and Africa, the prevalence and incidence of infectious diseases such as diarrhoea and malaria are at an all-time high. Governmental and non-governmental organizations, such as the World Health Organization, are attempting to reduce prevalence rates through early diagnosis with antimicrobial and antifungal kits. Furthermore, government tenders and partnerships with manufacturers are expected to provide a consistent revenue stream for the latter, thereby growing the anti-microbial/anti-fungal tests market as a whole.

Buy Anti-Microbial/ Anti-Fungal Tests Market Research Report- https://www.futuremarketinsights.com/checkout/5566